

Bioequivalence of Senaparib Manufactured at 2 Sites in Healthy Fasting Subjects
Details : Senaparib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 22, 2025

Bioequivalence Study of 10mg vs 20mg Senaparib Capsules in Healthy Chinese Under Fasting
Details : Senaparib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 13, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
Details : Paxonin (senaparib) is a PARP 1/2 inhibitor, received NMPA approval as monotherapy for adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian cancer.
Product Name : Paxonin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2025
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Details : Senaparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 01, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : IMPACT Therapeutics, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMP4927 (senaparib) is a PARP inhibitor, being investigated as monotherapy maintenance treatment following first-line platinum-based chemotherapy in patients with FIGO stage III/IV ovarian cancer who have achieved complete response or partial response.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 12, 2023
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : IMPACT Therapeutics, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Senaparib,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC
Details : The preliminary clinical results for a phase I b/II study investigating the PARP inhibitor IMP4297 having Senaparib in combination with temozolomide (TMZ) for the treatment of advanced solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2022
Lead Product(s) : Senaparib,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Impact Therapeutics Announces Completion of Series D1 Financing
Details : Proceeds will be used to accelerate the development of its synthetic lethality programs, including IMP4297, which are showing best-in-class potential. The company already has three synthetic lethality compounds in the clinical stage.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 14, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IMP9064,Senaparib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Burning Rock Dx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Burning Rock will provide the testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064, with worldwide intellectual property rights.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 04, 2021
Lead Product(s) : IMP9064,Senaparib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Burning Rock Dx
Deal Size : Undisclosed
Deal Type : Collaboration

Details : Senaparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 30, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Senaparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 17, 2020
Lead Product(s) : Senaparib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
